More precisely, combinations of RiBi inhibitors with drugs stabilizing p53 in a RiBi-independent manner, such as MDM2i and etoposide, restored efficient stabilization of p53 in BCL-2 overexpressing DLBCL cells. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.